Genetic Obesity and the Risk of Atrial Fibrillation: Causal Estimates from Mendelian Randomization

Neal A. Chatterjee, Harvard Medical School
Franco Giulianini, Harvard Medical School
Bastiaan Geelhoed, University of Groningen
Kathryn Lunetta, Framingham Heart Study
Jeffrey R. Misialek, University of Minnesota
Maartje N. Niemeijer, Erasmus Medical Center-University Medical Center
Michiel Rienstra, University of Groningen
Lynda M. Rose, Harvard Medical School
Albert V. Smith, Iceland Heart Assoc
Dan E. Arking, Johns Hopkins University

Only first 10 authors above; see publication for full author list.

Journal Title: Circulation
Volume: Volume 135, Number 8
Publisher: American Heart Association | 2017-02-21, Pages 741-+
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1161/CIRCULATIONAHA.116.024921
Permanent URL: https://pid.emory.edu/ark:/25593/s8btp

Final published version: http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024921

Copyright information:
© 2016 American Heart Association, Inc.

Accessed December 13, 2019 1:06 PM EST
Genetic Obesity and the Risk of Atrial Fibrillation – Causal Estimates from Mendelian Randomization

Neal A. Chatterjee, MD1, Franco Giulianini, PhD#1, Bastiaan Geelhoed, PhD#2, Kathryn L. Lunetta, PhD#3, Jeffrey R. Misialek, MPH#4, Maartje N. Niemeijer, MD, MSc#5, Michiel Rienstra, MD, PhD#2, Lynda M. Rose, MS#1, Albert V. Smith, PhD#6, Dan E. Arking, PhD7, Patrick T. Ellinor, MD, PhD8, Jan Heeringa, MD, PhD5, Honghuang Lin, PhD3,9, Steven A. Lubitz, MD, MPH8, Elsayed Z. Soliman, MD, MSc10, Niek Verweij, PhD2, Alvaro Alonso, MD, PhD11, Emelia J. Benjamin, MD, ScM3, Vilmundur Gudnason, MD, PhD6, Bruno H. C. Stricker, MMEd, PhD5, Pim Van Der Harst, MD, PhD2, Daniel I. Chasman, PhD1,^ and Christine M. Albert, MD, MPH1,12,#

1Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 2Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands 3The Framingham Heart Study, Framingham, MA, USA; Cardiology and Preventive Medicine Sections, Boston University School of Medicine, Epidemiology Department, Boston University School of Public Health, Boston, MA, USA 4Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA 5Department of Epidemiology, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands 6Icelandic Heart Association, Research Institute, Kpoavogur, Iceland and University of Iceland, Reykjavik, Iceland 7McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 8Cardiovascular Research Center and Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA, USA and Program in Medical and Population Genetics, The Broad Institute of Harvard and MIT, Cambridge, MA, USA 9Computational Biomedicine Section, Boston University School of Medicine, Boston, MA, USA 10Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston Salem, NC, USA 11Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 12Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

# These authors contributed equally to this work.

Abstract

Address for Correspondence: Neal A. Chatterjee, MD, Division of Preventive Medicine, Department of Medicine, Brigham Women’s Hospital, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, 900 Commonwealth Avenue, Boston, MA 02215, nchatterjee@partners.org, Phone: 617-732-5500, Fax: 617-277-0198, Twitter: @nchatterjeemd.

^ These authors jointly supervised this work.

Disclosures: Dr. Ellinor is the principle investigator on a grant from Bayer HealthCare to the Broad Institute focused on the genetics and therapeutics of atrial fibrillation.
Background—Observational studies have identified an association between body mass index (BMI) and incident atrial fibrillation (AF). Inferring causality from observational studies, however, is subject to residual confounding, reverse causation, and bias. The primary objective of this study was to evaluate the causal association between BMI and AF using genetic predictors of BMI.

Methods—We identified 51,646 individuals of European ancestry without AF at baseline from seven prospective population-based cohorts initiated between 1987 and 2002 in the United States, Iceland, and the Netherlands with incident AF ascertained between 1987 and 2012. Cohort-specific mean follow-up ranged 7.4 to 19.2 years, over which period there were a total of 4,178 cases of incident AF. We performed a Mendelian randomization with instrumental variable analysis to estimate a cohort-specific causal hazard ratio for the association between BMI and AF. Two genetic instruments for BMI were utilized: FTO genotype (rs1558902) and a BMI gene score comprised of 39 single nucleotide polymorphisms identified by genome-wide association studies to be associated with BMI. Cohort-specific estimates were combined by random-effects, inverse variance weighted meta-analysis.

Results—In age- and sex-adjusted meta-analysis, both genetic instruments were significantly associated with BMI (FTO: 0.43 [95% CI: 0.32 – 0.54] kg/m² per A-allele, p<0.001); BMI gene score: 1.05 [95% CI: 0.90-1.20] kg/m² per 1 unit increase, p<0.001) and incident AF (FTO – HR: 1.07 [1.02-1.11] per A-allele, p=0.004; BMI gene score – HR: 1.11 [1.05-1.18] per 1-unit increase, p<0.001). Age- and sex-adjusted instrumental variable estimates for the causal association between BMI and incident AF were HR 1.15 [1.04-1.26] per kg/m², p=0.005 (FTO) and 1.11 [1.05-1.17] per kg/m², p<0.001 (BMI gene score). Both of these estimates were consistent with the meta-analyzed estimate between observed BMI and AF (age- and sex-adjusted HR 1.05 [1.04-1.06] per kg/m², p<0.001). Multivariable adjustment did not significantly change findings.

Conclusions—Our data are consistent with a causal relationship between BMI and incident AF. These data support the possibility that public health initiatives targeting primordial prevention of obesity may reduce the incidence of AF.

Keywords
fibrillation; epidemiology; genetics; obesity; prevention

Introduction

Atrial fibrillation (AF) is the most common heart rhythm disturbance in the world with an estimated global prevalence of 34 million.1,2 The sheer size of this population represents a major public health burden underscored by the myriad consequences of AF, which include thromboembolic stroke,3 heart failure (HF),4 cognitive dysfunction,5 and increased mortality.6 The incidence of AF also appears to be increasing,7,8 even after accounting for the ageing population,7,9,10 suggesting that the increasing prevalence of other AF risk factors may be driving at least part of this observed trend.

Epidemic increases in the prevalence of obesity have coincided with the expanding global burden of AF,5,11 and consistent associations between obesity and incident AF have been reported in several prospective cohort studies.12-17 Longitudinal changes in body mass index (BMI) have been associated with concordant change in AF risk,15,16 further suggesting a
potential to modify AF risk with weight interventions. Given that approximately one third of
the world’s population is estimated to be overweight or obese, targeting obesity – through
both preventive and weight reduction strategies – has the potential to greatly lower the
incidence of AF if the observed associations between BMI and AF are causal. However, it
is not possible to establish causality solely on the basis of observational analyses, which
remain vulnerable to residual confounding, reverse causation, and bias. To date, there have
been no ‘gold-standard’ randomized controlled trials of obesity interventions for the primary
prevention of AF.

In this context, Mendelian randomization analysis – using genetic instruments which are
randomly assigned during meiosis and therefore unlikely to be related to potential
confounders – is an alternative approach that can be used to infer the extent of causality
between a proposed risk factor and outcome (e.g. BMI and incident AF). Therefore, in our
study, we employ Mendelian randomization techniques to test the hypothesis that the known
positive observational relationship between BMI and incident AF is causal.

Methods

Study Population
The study population was drawn from seven prospective cohorts studies conducted in the
United States and Europe: the Age, Gene/Environment Susceptibility Reykjavik Study
(AGES), the Atherosclerosis Risk in Communities (ARIC) study, the Framingham Heart
Study (FHS), the Prevention of Renal and Vascular End-stage Disease (PREVEND) study,
the Rotterdam Study (RS-I and RS-II), and the Women’s Genome Healthy Study (WGHS). Detailed information for the participating cohorts is provided in the Supplemental
Material. Inclusion criteria for our study required complete genome-wide genotyping data
and European ancestry verified by principle components analysis. Exclusion criteria
included the presence of AF at enrollment and missing covariates of interest. The
Institutional Review Boards at each participating institution approved the individual studies
and study participants provided written informed consent.

Assessment of AF
AF was assessed using cohort-specific methodology including physician-adjudication,
electrocardiography, and diagnosis codes for AF or flutter (ICD-9-CM 427.3, 427.31 or
427.32; ICD-10 I48) present in hospitalization discharges or death certificates. Further
details of AF ascertainment in each cohort are available in the Supplemental Material.

Assessment of BMI and Covariates
BMI was measured at study baseline and calculated as the ratio of weight (kg) and height
squared (m²). Anthropomorphic measures were assessed directly in all studies with the
exception of WGHS, in which measures were assessed using a questionnaire. Other
covariates relevant to incident AF including self-reported smoking history and alcohol
consumption, systolic and diastolic blood pressure, anti-hypertensive medication use, height,
and history of medical comorbidities (diabetes, HF, coronary heart disease) were collected
according to study-specific protocols (see Supplemental Material). Protocols for covariate ascertainment and definitions were comparable across studies.

**Genotyping and Genetic Risk Score (BMI Gene Score)**

Genotyping methodology within the AFGen consortium has been described elsewhere, and an overview is provided in the Supplemental Material (Supplemental Table 1).23 We first derived a genetic instrument using the FTO single-nucleotide polymorphism (SNP; rs1558902) given that this locus demonstrated the strongest association with BMI in previous genetic analyses.24 To improve the precision of instrumental variable estimates,25 we then selected 38 additional SNPs previously validated in replication cohorts to be significantly associated with BMI at genome-wide significance (Supplemental Table 2).24,26 A weighted genetic score (BMI gene score) comprised of these 39 SNPs was constructed for each individual by summing the number of inherited BMI-increasing alleles of each SNP weighted by their effect size.27

**Statistical Analysis**

The FTO SNP (rs1558902) and the BMI gene score were used as genetic instrumental variables for all analyses, and measures of BMI taken at study baseline were used as the observational exposure variable. Follow-up time was defined from study baseline until the first occurrence of AF, death, loss to follow-up, or end of study period. Within each cohort, the association of both instrumental variables (FTO, BMI gene score) with BMI was assessed using linear regression. Cox proportional hazards models were used to evaluate the observational association between BMI at study enrollment and incident AF. Cox models were also used to estimate the relative risk of incident AF associated with both instruments (BMI gene score and FTO). All models were initially adjusted for age and sex. Given that the validated SNPs associated with BMI at genome-wide significance were identified in models adjusted for age and age-squared,24,26 instrument-BMI models were additionally adjusted for age-squared. Subsequently, the following covariates were added to this model in a sequential fashion. Model 2 additionally adjusted for smoking status and alcohol intake. Model 3 additionally adjusted for comorbidities that may either mediate or confound the BMI-AF relationship including hypertension (systolic and diastolic blood pressure, anti-hypertensive medication use), diabetes mellitus, and history of HF or coronary heart disease at study entry. The final model (Model 4) further adjusted for height to account for the known effects of height on AF risk, distinct from its implicit contribution to BMI.28,29 In the FHS cohort, incident analyses were performed using Cox proportional hazards regression with a robust variance estimator clustering by family to adjust for relatedness. In the ARIC cohort, as participants were enrolled at more than one site, all models were additionally adjusted for study site. To assess if the associations between the genetic instruments and AF were mediated by BMI, instrument-AF models were adjusted for BMI measured at study baseline. There were no violations of the proportional hazards assumption in all models.

A causal hazard ratio for the association of BMI with incident AF was derived using the Wald-type estimator with standard errors estimated by the delta method.30,31 Briefly, the Wald estimator is the ratio of the log of the hazard ratio of the genetic instrument-AF association and the linear regression coefficient of the genetic instrument-BMI association.
Exponentiation of this ratio yields a hazard ratio estimating the causal relationship between BMI and incident AF. Cohort-specific estimates were pooled using random-effects, inverse variance weighted meta-analysis. The pooled effect estimates for the BMI gene score were derived per 1-unit change and additionally reported per 1-standard deviation change, using a global standard deviation derived as the square root of the sample-size weighted mean of cohort-specific squared standard deviations. Heterogeneity was assessed with the $I^2$ and Cochrane Q statistics ($Q_p$),\textsuperscript{32} and potential sources of heterogeneity were explored with meta-regression.\textsuperscript{33,34} A Wald test was used to assess the significance of the difference between the observational and instrumental variable estimates. To assess the stability of estimating the cohort-specific standard errors of the Wald estimator, the overall instrumental estimate was also constructed with an alternative strategy using initial meta-analysis of the instrument:BMI and instrument:AF associations across cohorts followed by derivation of the Wald estimator. As results did not differ significantly between these approaches (Supplemental Table 4), presentation of the meta-analysis of cohort-specific instrumental variable estimates was prioritized. Statistical analysis was performed using R software version 3.2.1 (R Project for Statistical Computing) or SAS version 9.3 (SAS Institute, Cary, NC). A 2-tailed $P < 0.05$ was considered to indicate statistical significance.

Results

Study Cohorts

Baseline characteristics for the seven contributing populations totaling 51,646 participants free of AF at baseline are shown in Table 1. The mean age at study enrollment ranged from 49 to 76 years whereas mean BMI at study enrollment ranged from 25.9 to 27.2 kg/m\textsuperscript{2}. Overall, more women than men were included (N=37,430; 72% of study cohort). Cohort-specific mean follow-up ranged 7.4 to 19.2 years, over which period there were a total of 4178 cases of incident AF.

BMI and Incident AF: Observational Risk Estimates

In observational analysis, increasing BMI was associated with uniformly significant increased risk of incident AF. Study-specific increments in risk ranged from 3 to 6% per 1 kg/m\textsuperscript{2} increase in BMI (Table 2). In age- and sex-adjusted analysis, the pooled hazard ratio for incident AF was 1.05 per kg/m\textsuperscript{2} [95% CI: 1.04-1.06] ($p < 0.001$) without significant heterogeneity ($I^2 = 24.1\%$, $Q_p = 0.37$). Additional adjustment for potential confounders (Model 2: smoking, alcohol use), potential intermediaries in the causal pathway between BMI and AF (Model 3: hypertension, diabetes mellitus, HF, coronary heart disease), and height (Model 4) minimally changed the association between BMI and AF (Model 4: HR 1.04 [95% CI: 1.03-1.05], $p < 0.001$; $I^2 = 0\%$, $Q_p = 0.78$) (Table 2).

Genetic Instruments and BMI

Cohort-specific genetic instruments (FTO, BMI gene score) are summarized in Table 1. The coded allele frequency (CAF) for the FTO SNP (rs1558902) associated with increasing BMI was comparable across studies (range: 38-42%). The BMI gene score had a cohort-specific mean of 4.1±0.5 in all cohorts. In age- and sex-adjusted analysis, each instrument was associated with significant increase in BMI with effect sizes ranging 0.21 to 0.55 kg/m\textsuperscript{2} per
A-allele of the *FTO* SNP and 0.78 to 1.25 kg/m$^2$ per 1-unit increase in BMI gene score (p < 0.001 for both meta-analyzed instrument-BMI associations; Figure 1). The association between both instruments and BMI demonstrated moderate heterogeneity across studies (*FTO*: $I^2 = 67.9\%$, Qp < 0.01; BMI gene score: $I^2 = 72.3\%$, Qp <0.01 in age- and sex-adjusted models) with greater instrument-BMI effect size in cohorts with younger populations (p, for association of mean cohort age and instrument-BMI effect size = 0.01 (*FTO*) and 0.004 (BMI gene score); **Supplemental Figure 1**). Heterogeneity was substantially attenuated following meta-regression accounting for differences in mean age between cohorts (residual heterogeneity: *FTO*: $I^2 = 37.5\%$, Qp = 0.17; BMI gene score: $I^2 = 37.5\%$, Qp = 0.16 in age- and sex-adjusted models). There was no material change in the instrument-BMI effect size in multivariable-adjusted models (**Supplemental Figure 2**) and moderate heterogeneity in these models was similarly attenuated in meta-regression accounting for mean cohort age (**Supplemental Table 3**).

**Genetic Instruments and Incident AF**

We next examined the relationship between the genetic instruments and incident AF. Study-specific associations and pooled estimates from meta-analysis between both instruments (*FTO*, BMI gene score) and incident AF are shown in **Figure 2**. In meta-analysis of age- and sex-adjusted models, increase in both instruments was associated with a significantly increased risk of incident AF (*FTO*: HR 1.07 [95% CI: 1.02-1.12] per A-allele of the *FTO* SNP, p=0.004); BMI gene score: HR 1.11 [95% CI: 1.05-1.18] per 1-unit increase in BMI gene score, p<0.001) with minimal heterogeneity across studies (*FTO*: $I^2 = 0\%$, Qp=0.83; BMI gene score: $I^2 = 0\%$, Qp=0.73). Adjustment for potential confounders, potential causal intermediaries, and height did not meaningfully change the instrument-AF associations (**Figure 2**) with minimal heterogeneity across studies in adjusted analyses (**Supplemental Table 3**). In contrast, adjustment of the instrument-AF associations for BMI measured at study baseline yielded non-significant associations between the genetic instruments and incident AF in all models, consistent with mediation of the instrument-AF association by BMI (**Figure 2D**; **Supplemental Figure 3**).

**BMI and Incident AF: Causal Inference Using Instrumental Variable Analysis**

Given the separate and significant associations of the genetic instruments with BMI and incident AF, we combined these effects to derive an instrumental variable estimate of the association between BMI and AF for each cohort (**Table 3**). In meta-analysis of instrumental variable estimates from age- and sex-adjusted models, each 1 kg/m$^2$ increase in BMI was associated with a significantly increased risk of incident AF for both *FTO* (HR 1.15 [95% CI: 1.05-1.27], p=0.004) and the BMI gene score (HR 1.11 [95% CI: 1.05-1.17], p<0.001) with minimal heterogeneity across studies (*FTO*: $I^2 = 0\%$, Qp=0.91; BMI gene score: $I^2 = 0\%$, Qp=0.91). Both of these estimates were numerically larger than the observational estimates from age- and sex-adjusted models (HR=1.05 [95% CI: 1.04-1.06] per 1 kg/m$^2$ increase; **Table 2**) although not statistically significantly different (p, for comparison of instrumental vs. observational estimates: *FTO*: 0.063, BMI gene score: 0.061). Adjustment for confounders, potential causal intermediaries, and height did not change the instrumental estimates (**Table 3**). To assess the robustness of our approach, we derived the instrumental
estimates of the BMI-AF association using study-combined estimates of the genetic instrument-BMI and genetic-instrument-AF associations. The estimated causal effects of BMI and incident AF with this alternative approach were similar to meta-analysis of study-specific instrumental variable estimates (Supplemental Table 4).

Discussion

In our prospective cohorts of over 50,000 individuals without AF at baseline, genetic variants associated with increasing BMI were significantly associated with incident AF. We show that measured BMI mediates at least a portion of the effect of these genetic variants on incident AF, whereas accounting for other AF risk factors had no impact on the genetic instrument-AF risk estimates. Taken together, these data support a causal relationship between obesity and incident AF and further suggest an important role for obesity-targeted public health interventions to combat the expanding global epidemic of AF.

There are several lines of evidence from observational and small-scale randomized studies in support of a causal relationship between obesity and AF. First, strong and consistent dose response relationships between BMI and incident AF have been documented in several large-scale prospective cohort studies (~3-5% increased risk of AF per kg/m\(^2\) increase in BMI). A remarkably similar association was identified in meta-analysis of observational estimates in the present study. Second, prospective studies have shown an association between longitudinal reductions in BMI and decreased incident AF. Third, among patients with established AF, sustained weight loss has been associated with reductions in AF in both observational studies and randomized trials. For example, in the recently reported LEGACY-AF (Long-Term Effect of Goal Directed Weight Management on Atrial Fibrillation Cohort) study of obese patients (BMI ≥27 kg/m\(^2\)) with AF, weight loss of ≥10% was associated with a 6-fold decrease in AF recurrence at 5 years. Extending these observational findings, a recent small, randomized controlled trial in 150 obese patients with AF demonstrated significant reductions in AF burden and symptom severity scores with weight-loss intervention compared to general lifestyle advice. In contrast, the efficacy of lifestyle intervention for the primary prevention of AF is less well established. For example, randomization of obese individuals with diabetes mellitus to an intensive lifestyle intervention was not associated with a reduced incidence of AF in the presence of modest weight loss.

Compelling as these data may be, observational risk estimates of the BMI-AF relationship are intrinsically subject to important limitations in causal inference. First, all observational studies are vulnerable to the risk of residual confounding which may bias estimates. More specifically, participants who are overweight or who do not lose weight likely differ from those who maintain or attain a normal BMI in many other respects that may be related to AF. By comparison, the use of BMI-associated genotypes which are randomly assigned at meiosis significantly attenuates this source of bias. For example, the FTO SNP and the genetic variants utilized in our BMI gene score have been previously shown to be unrelated to known cardiovascular disease risk factors which may confound the relationship between BMI and AF. Second, observational risk estimates associated with obesity and weight loss are subject to ‘reverse causation’ bias in which subclinical manifestations of the disease of
interest (eg. AF) may lead to illness-induced weight change. In our study, use of genetic instruments, which are immutable and randomly allocated at conception, almost entirely eliminates this potential source of bias.

Third, observational studies which account for cumulative BMI exposure have identified greater cardiovascular risk estimates when compared to cross-sectional BMI assessment. Taken further, BMI-associated genetic variants may better reflect lifetime exposure to obesity (i.e. ‘area under the BMI curve’) when compared to a one-time measure or even repeated measures of BMI recorded during cohort studies. This might account for the numerically, albeit non-significantly, greater estimated causal effect of BMI on incident AF we obtained using genetic instruments compared to observational estimates. Similar discordance in instrumental and observational estimates has been reported for the association between BMI-increasing genetic variants and coronary disease risk. Alternatively, pleiotropy – in which the selected genetic variants mediate AF risk through a non-BMI pathway – might account for some of the discordance in risk estimates. The association between the genetic instruments and AF, however, remained significant after adjustment for several possible pleiotropic mediators including hypertension and coronary heart disease. In addition, our finding that adjustment for observed BMI nullified the statistical association between the genetic instruments and AF supports BMI as the causal mediator of the association between the genetic instruments and incident AF, and argues against a major contribution from pleiotropic effects.

There are several potential mechanisms which may underlie a causal relationship between BMI and incident AF. Obesity has been linked to both cardiac structural pathology and systemic processes associated with the development of AF. For example, obesity has been associated with left atrial enlargement and left ventricular diastolic impairment, both of which predispose to AF. Similarly, obesity has been associated with a systemic inflammatory state which, in turn, has been associated with an increased risk of AF. More proximate to the anatomic substrate of AF, increasing BMI has also been associated with epicardial fat which is a risk factor for incident AF in community cohorts. Epicardial fat may directly modify the electrical atrial substrate through local perturbation of autonomic balance, elaboration of pro-fibrotic adipokines, and induction of oxidative stress pathways implicated in AF pathogenesis. Weight loss has been associated with improvements in diastolic function, decrease in systemic inflammatory markers, and a decline in pericardial fat volume, each reflecting possible mechanisms of the salutary effects of obesity interventions in AF. Finally, increased BMI is associated with incident cardiovascular disease that may further increase the risk of AF (eg. hypertension, HF, myocardial infarction).

Despite major advances in stroke prophylaxis and ablative therapy, AF remains a significant cause of morbidity and mortality. To the extent that obesity is causally associated with AF as suggested by our study, the impact of obesity-focused public health interventions for the primary prevention of AF could be quite substantial. Observational studies have estimated that up to 12-18% of AF may be attributable to obesity, and recent data suggest that the attributable risk associated with obesity has increased over the past 50 years in conjunction with the rising prevalence of obesity. Our data also support...
a potential cumulative impact of BMI exposure on AF, which might serve to reinforce the importance of durable weight maintenance after obesity interventions and place further emphasis on the primordial prevention of obesity.

**Limitations**

The results of our study should be interpreted in the context of its study design. Causal inference using Mendelian randomization is predicated on several specific design criteria including consistent genotype-to-exposure effect estimates. In our study, the magnitude of the significant associations between genetic instruments and increasing BMI were moderately heterogeneous and stronger in cohorts with a lower mean age. BMI at older ages is more likely to be influenced by the development of comorbid illness, which may confound the BMI-AF association and decrease the specificity of BMI as a pathophysiological surrogate of AF risk (e.g., for adiposity, epicardial fat). Second, AF ascertainment was not systematically harmonized across studies, although the large sample size (> 50,000 participants) augmented the precision of effect estimates, and associations between observational and genetic instruments with AF were consistent across cohorts. Third, genetic variants associated with BMI are known to explain only a minority of the variation in BMI, thus decreasing the power of these instruments to detect significant exposure-outcome association and potentially inflating bias related to violations of instrumental variable assumptions (e.g., absent pleiotropy). The use of a weighted genetic score, as employed in our study, mitigated both of these risks. Fourth, additional SNPs not included in our gene score have been recently associated with BMI in GWAS. Given the reported per allele effect estimates, we would estimate that these SNPs in toto would account for no more than 0.6% of the variance in BMI (assuming an additive contribution) and therefore inclusion of these identified gene variants would be unlikely to alter the findings of our study. Finally, our study included participants of European ancestry, and therefore our findings may not be generalizable to non-European individuals.

**Conclusion**

In summary, in this Mendelian randomization study of over 50,000 individuals of European ancestry, genetic variants associated with BMI were significantly associated with an increased risk of incident AF and instrumental variable analysis supported a causal relationship between BMI and AF. These data augment support for the primordial prevention of obesity as a public health target to combat the expanding global burden of AF.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

Funding

Dr. Alonso is supported by American Heart Association grant 16EIA26410001. Dr. Chatterjee is supported by NHLBI T-32 HL-007575 (Bethesda, Maryland). Dr. Ellinor is supported by an Established Investigator Award from the American Heart Association (13EIA14220013) and by the Foundation Leducq (14CVD01). Dr. Lubitz is supported by NIH grant K23HL114724 and a Doris Duke Charitable Foundation Clinical Scientist Development
Award 2014105. Dr. Rienstra is supported by a grant from the Netherlands Organization for Scientific Research (Veni grant 016-36-055).

AGES: The Age, Gene/Environment Susceptibility-Reykjavik Study was supported by National Institutes of Health (contracts N01-AG-12100 and HHSN27120120002C), the National Institute on Aging Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

FHS: The Framingham Heart Study is supported by National Heart, Lung, and Blood Institute contracts HHSN2682015000011; N01-HC 25195; R01HL092577; R01HL128914; completed 1R01 HL102214; 1R1HL101056; K24HL105780.

PREVEND: The Prevention of Renal and Vascular End-Stage Disease study is supported by the Dutch Kidney Foundation (grant E0.13) and the Netherlands Heart Foundation (NHS2010B280).

Rotterdam Study: The Rotterdam Study is supported by the Erasmus MC University Medical Center, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development, the Netherlands Genomics Initiative, and the municipality of Rotterdam. The authors thank the staff and participants from the Ommoord district.

WGHS: The Women’s Genome Health Study and AF endpoint confirmation was supported by HL043851, HL080467, HL093613, and HL099355 (completed) from the National Heart, Lung, and Blood Institute, CA047988 (completed) and UM1CA182913 from the National Cancer Institute, and the Watkin’s Foundation, with collaborative scientific support and funding for genotyping provided by Amgen.

References


Clinical Perspective

What Is New?

- Mendelian randomization utilizes genetic variants associated with a proposed risk factor to infer the causal association between a risk factor and an outcome.

- In this study of more than 50,000 European individuals without atrial fibrillation (AF) at baseline, genetic variants associated with increasing body mass index (BMI) were significantly associated with an increased risk of AF.

- The association between genetically determined obesity and AF persisted even after adjustment for traditional AF risk factors including hypertension, diabetes mellitus, coronary artery disease, and heart failure.

- Taken together, these data are consistent with a causal association between increasing BMI and AF.

What Are the Clinical Implications?

- Our findings augment support for the primordial prevention of obesity as a significant public health target to combat the expanding global burden of AF.

- Our findings also highlight the potential impact of cumulative exposure to obesity and risk of AF which, in turn, has implications for both the timing and durability of obesity interventions.
Figure 1. Association between Genetic Instruments and BMI
Study-specific and meta-analyzed pooled associations between each genetic instrument
(FTO, BMI gene score) and BMI (kg/m$^2$) are shown, adjusted for age, age-squared, and sex.
Effect estimates are per A-allele of FTO or change in BMI gene score (1-unit increase and 1
STDEV change). $I^2$ reflects heterogeneity across studies with greater values reflecting
greater heterogeneity. Qp reflects Cochran’s Q statistic, a test for heterogeneity. BMI, body
mass index. STDEV, standard deviation.
Figure 2. Association between Genetic Instruments and AF

Shown are study-specific and meta-analyzed pooled estimates for the associations between each genetic instrument (FTO, BMI gene score) and risk of incident AF. Effect estimates are per A-allele of FTO or change in BMI gene score (1-unit increase and 1 STDEV change).

(A) Shown are age- and sex-adjusted associations (Model 1) as well as (B) multivariable models which include additional adjustment for smoking status and alcohol intake (Model 2). (C) Multivariable models were subsequently adjusted for possible mediators of the BMI-AF association (systolic and diastolic blood pressure, anti-hypertensive medication use, diabetes mellitus, previous heart failure or coronary heart disease) as well as height (Model 4). (D) Finally, to assess if the genetic instrument-AF association was mediated by BMI, models were adjusted for BMI measured at the time of cohort baseline. $I^2$ reflects heterogeneity across studies with greater values reflecting greater heterogeneity. Qp reflects Cochran’s Q statistic, a test for heterogeneity. BMI; body mass index; STDEV, standard deviation.
Table 1

Baseline Characteristics Study Cohorts

<table>
<thead>
<tr>
<th></th>
<th>AGES (n=2953)</th>
<th>ARIC (n=9276)</th>
<th>FHS (n=7509)</th>
<th>PREVEND (n=3515)</th>
<th>RS-I (n=5729)</th>
<th>RS-II (n=2087)</th>
<th>WGHS (n=20577)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>76 (5)</td>
<td>54 (6)</td>
<td>51 (15)</td>
<td>49 (12)</td>
<td>69 (9)</td>
<td>65 (8)</td>
<td>54 (7)</td>
</tr>
<tr>
<td>Men</td>
<td>1341 (42%)</td>
<td>4356 (47%)</td>
<td>3459 (46%)</td>
<td>1809 (51%)</td>
<td>2302 (40%)</td>
<td>949 (46%)</td>
<td>-</td>
</tr>
<tr>
<td>Height, cm</td>
<td>167 (9)</td>
<td>169 (9)</td>
<td>169 (10)</td>
<td>174 (9)</td>
<td>167 (9)</td>
<td>170 (9)</td>
<td>164 (6)</td>
</tr>
<tr>
<td>Current cigarette smoking</td>
<td>378 (13%)</td>
<td>2293 (25%)</td>
<td>1183 (16%)</td>
<td>1235 (35%)</td>
<td>1324 (23%)</td>
<td>470 (23%)</td>
<td>2315 (11%)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>27.1 (4.4)</td>
<td>27.0 (4.9)</td>
<td>27.0 (5.1)</td>
<td>26.1 (4.2)</td>
<td>26.3 (3.7)</td>
<td>27.2 (4.0)</td>
<td>25.9 (4.9)</td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>143 (20)</td>
<td>118 (17)</td>
<td>123 (18)</td>
<td>129 (20)</td>
<td>139 (22)</td>
<td>143 (21)</td>
<td>123 (14)</td>
</tr>
<tr>
<td>DBP, mmHg</td>
<td>74 (10)</td>
<td>72 (10)</td>
<td>75 (10)</td>
<td>74 (10)</td>
<td>74 (11)</td>
<td>79 (11)</td>
<td>77 (9)</td>
</tr>
<tr>
<td>Hypertensive medication</td>
<td>1834 (62%)</td>
<td>2344 (25%)</td>
<td>1578 (21%)</td>
<td>416 (14%)</td>
<td>1730 (30%)</td>
<td>566 (27%)</td>
<td>2610 (13%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>326 (11%)</td>
<td>795 (9%)</td>
<td>443 (6%)</td>
<td>133 (4%)</td>
<td>571 (10%)</td>
<td>219 (11%)</td>
<td>497 (2%)</td>
</tr>
<tr>
<td>Previous heart failure</td>
<td>49 (2%)</td>
<td>334 (4%)</td>
<td>40 (0.5%)</td>
<td>6 (0.2%)</td>
<td>139 (2%)</td>
<td>18 (1%)</td>
<td>-</td>
</tr>
<tr>
<td>Previous coronary heart disease</td>
<td>495 (17%)</td>
<td>454 (5%)</td>
<td>419 (6%)</td>
<td>28 (1%)</td>
<td>431 (8%)</td>
<td>128 (6%)</td>
<td>-</td>
</tr>
<tr>
<td>EtOH Consumption ≥ 2 drinks/day</td>
<td>23 (1%)</td>
<td>594 (6%)</td>
<td>7243 (96%)*</td>
<td>943 (27%)*</td>
<td>916 (16%)</td>
<td>390 (19%)</td>
<td>838 (4%)</td>
</tr>
<tr>
<td>Body mass index gene score</td>
<td>4.1 (0.5)</td>
<td>4.1 (0.5)</td>
<td>4.1 (0.5)</td>
<td>4.1 (0.5)</td>
<td>4.1 (0.5)</td>
<td>4.1 (0.5)</td>
<td>4.1 (0.5)</td>
</tr>
<tr>
<td>FTO variant (rs1558902) CAF, %</td>
<td>40</td>
<td>41</td>
<td>42</td>
<td>40</td>
<td>38</td>
<td>40</td>
<td>41</td>
</tr>
<tr>
<td># Atrial fibrillation cases</td>
<td>422 (14%)</td>
<td>1373 (15%)</td>
<td>555 (7%)</td>
<td>113 (3%)</td>
<td>693 (12%)</td>
<td>80 (4%)</td>
<td>942 (5%)</td>
</tr>
<tr>
<td>Mean follow-up time, years</td>
<td>7.4 (2.5)</td>
<td>19.2 (5.5)</td>
<td>8.4 (3.2)</td>
<td>9.6 (2.3)</td>
<td>12.7 (5.7)</td>
<td>8.4 (1.9)</td>
<td>18.0 (3.3)</td>
</tr>
</tbody>
</table>

Values correspond to N (%) or mean (standard deviation). Body mass index (BMI) gene score reflects a weighted sum of BMI increasing alleles of 39 single nucleotide polymorphisms (see Methods).

AGES, indicates the Age, Gene/Environment Susceptibility—Reykjavik study; ARIC, Atherosclerosis Risk in Communities; FHS, Framingham Heart Study; PREVEND, Prevention of Renal and Vascular End-Stage Disease; RS, Rotterdam Study; WGHS, Women’s Genome Health Study; SBP, systolic blood pressure; DBP, diastolic blood pressure; EtOH, alcohol; CAF, coded allele frequency for FTO SNP (rs1558902) associated with increasing body mass index.

* >0 drinks/day;
† ≥1 drink/day.
<table>
<thead>
<tr>
<th></th>
<th>AGES</th>
<th>ARIC</th>
<th>FHS</th>
<th>PREVEND</th>
<th>RS-I</th>
<th>RS-II</th>
<th>WGHS</th>
<th>Meta-Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1 (HR, 95% CI)</td>
<td>1.03 (1.01-1.05)</td>
<td>1.06 (1.05-1.07)</td>
<td>1.05 (1.03-1.06)</td>
<td>1.06 (1.01-1.10)</td>
<td>1.05 (1.03-1.07)</td>
<td>1.05 (1.00-1.11)</td>
<td>1.05 (1.04-1.06)</td>
<td><strong>1.05 (1.04-1.06)</strong></td>
</tr>
<tr>
<td>Model 2 (HR, 95% CI)</td>
<td>1.03 (1.01-1.06)</td>
<td>1.07 (1.06-1.08)</td>
<td>1.05 (1.03-1.07)</td>
<td>1.05 (1.01-1.10)</td>
<td>1.05 (1.02-1.07)</td>
<td>1.05 (0.97-1.11)</td>
<td>1.05 (1.04-1.06)</td>
<td><strong>1.05 (1.04-1.06)</strong></td>
</tr>
<tr>
<td>Model 3 (HR, 95% CI)</td>
<td>1.03 (1.01-1.05)</td>
<td>1.05 (1.03-1.06)</td>
<td>1.04 (1.02-1.06)</td>
<td>1.05 (1.00-1.11)</td>
<td>1.03 (1.00-1.05)</td>
<td>1.03 (0.97-1.11)</td>
<td>1.03 (1.02-1.05)</td>
<td><strong>1.04 (1.03-1.05)</strong></td>
</tr>
<tr>
<td>Model 4 (HR, 95% CI)</td>
<td>1.03 (1.01-1.05)</td>
<td>1.05 (1.03-1.06)</td>
<td>1.04 (1.02-1.06)</td>
<td>1.04 (1.01-1.10)</td>
<td>1.04 (1.01-1.06)</td>
<td>1.03 (0.97-1.10)</td>
<td>1.04 (1.03-1.05)</td>
<td><strong>1.04 (1.03-1.05)</strong></td>
</tr>
</tbody>
</table>

Meta-Analysis

<table>
<thead>
<tr>
<th>Observational estimate</th>
<th>1.05 (1.04-1.06)</th>
<th>1.05 (1.04-1.06)</th>
<th>1.04 (1.03-1.05)</th>
<th>1.04 (1.03-1.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test for overall effect</td>
<td>p&lt;0.001</td>
<td>p&lt;0.001</td>
<td>p&lt;0.001</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Heterogeneity [I², Qp]</td>
<td>[24%, 0.37]</td>
<td>[47.5%, 0.10]</td>
<td>[5.1%, 0.68]</td>
<td>[0%, 0.78]</td>
</tr>
</tbody>
</table>

I² reflects heterogeneity between studies with higher values reflecting greater heterogeneity. Qp reflects Cochran’s Q statistic, a test for heterogeneity. AF, atrial fibrillation; BMI, body mass index; HR, hazard ratio; CI, confidence interval; AGES: Age, Gene/Environment Susceptibility—Reykjavik study; ARIC, Atherosclerosis Risk in Communities; FHS, Framingham Heart Study; PREVEND, Prevention of Renal and Vascular End-stage Disease; RS, Rotterdam Study; WGHS, Women’s Genome Health Study. Model 1: adjustment for age and sex. Model 2: Model 1 + smoking status, alcohol intake. Model 3: Model 2 + potential mediators of BMI-AF association (systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, diabetes, previous coronary heart disease and previous heart failure). Model 4: Model 3 + height.
Table 3

Association of BMI and Incident AF: Instrumental Variable Estimates

<table>
<thead>
<tr>
<th>Instrument = FTO Score</th>
<th>Model 1 (HR, 95% CI)</th>
<th>Model 2 (HR, 95% CI)</th>
<th>Model 3 (HR, 95% CI)</th>
<th>Model 4 (HR, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGES</td>
<td>1.37 (0.86-2.17)</td>
<td>1.30 (0.86-1.96)</td>
<td>1.33 (0.83-2.13)</td>
<td>1.36 (0.82-2.24)</td>
</tr>
<tr>
<td>ARIC</td>
<td>1.08 (0.93-1.25)</td>
<td>1.10 (0.95-1.28)</td>
<td>1.07 (0.90-1.27)</td>
<td>1.07 (0.90-1.27)</td>
</tr>
<tr>
<td>FHS</td>
<td>1.19 (0.95-1.49)</td>
<td>1.18 (0.94-1.47)</td>
<td>1.20 (0.94-1.52)</td>
<td>1.21 (0.94-1.56)</td>
</tr>
<tr>
<td>PREVEND</td>
<td>1.12 (0.56-2.24)</td>
<td>1.13 (0.55-2.33)</td>
<td>0.80 (0.36-1.80)</td>
<td>0.86 (0.37-1.96)</td>
</tr>
<tr>
<td>RS-I</td>
<td>1.15 (0.68-1.94)</td>
<td>1.03 (0.64-1.67)</td>
<td>1.04 (0.58-1.85)</td>
<td>1.08 (0.59-1.96)</td>
</tr>
<tr>
<td>RS-II</td>
<td>0.90 (0.36-2.27)</td>
<td>0.93 (0.36-2.39)</td>
<td>1.06 (0.35-3.21)</td>
<td>1.05 (0.34-3.23)</td>
</tr>
<tr>
<td>WGHS</td>
<td>1.23 (1.03-1.47)</td>
<td>1.23 (1.03-1.47)</td>
<td>1.24 (0.99-1.56)</td>
<td>1.25 (0.99-1.57)</td>
</tr>
</tbody>
</table>

Meta-Analysis

<table>
<thead>
<tr>
<th>IV Estimate</th>
<th>Test for overall effect</th>
<th>Heterogeneity [I^2, Qp]</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGES</td>
<td>1.15 (1.05-1.27)</td>
<td>p=0.004 [0%, 0.91]</td>
</tr>
<tr>
<td>ARIC</td>
<td>1.15 (1.05-1.27)</td>
<td>p=0.003 [0%, 0.95]</td>
</tr>
<tr>
<td>FHS</td>
<td>1.14 (1.02-1.28)</td>
<td>p=0.03 [0%, 0.87]</td>
</tr>
<tr>
<td>PREVEND</td>
<td>1.15 (1.03-1.29)</td>
<td>p=0.019 [0%, 0.88]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Instrument = BMI Gene Score</th>
<th>Model 1 (HR, 95% CI)</th>
<th>Model 2 (HR, 95% CI)</th>
<th>Model 3 (HR, 95% CI)</th>
<th>Model 4 (HR, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGES</td>
<td>1.05 (0.86-1.29)</td>
<td>1.05 (0.85-1.30)</td>
<td>1.06 (0.85-1.32)</td>
<td>1.06 (0.87-1.30)</td>
</tr>
<tr>
<td>ARIC</td>
<td>1.13 (1.04-1.23)</td>
<td>1.13 (1.04-1.23)</td>
<td>1.10 (1.01-1.21)</td>
<td>1.10 (1.01-1.21)</td>
</tr>
<tr>
<td>FHS</td>
<td>1.14 (0.99-1.30)</td>
<td>1.13 (0.99-1.30)</td>
<td>1.13 (0.98-1.31)</td>
<td>1.12 (0.97-1.30)</td>
</tr>
<tr>
<td>PREVEND</td>
<td>1.05 (0.75-1.47)</td>
<td>1.02 (0.72-1.44)</td>
<td>1.01 (0.69-1.50)</td>
<td>1.08 (0.72-1.62)</td>
</tr>
<tr>
<td>RS-1</td>
<td>1.06 (0.88-1.27)</td>
<td>1.05 (0.84-1.30)</td>
<td>1.03 (0.82-1.29)</td>
<td>1.04 (0.83-1.30)</td>
</tr>
<tr>
<td>RS-2</td>
<td>0.84 (0.50-1.43)</td>
<td>0.84 (0.50-1.41)</td>
<td>0.84 (0.47-1.50)</td>
<td>0.82 (0.46-1.47)</td>
</tr>
<tr>
<td>WGHS</td>
<td>1.10 (0.99-1.21)</td>
<td>1.09 (0.99-1.21)</td>
<td>1.08 (0.96-1.21)</td>
<td>1.07 (0.95-1.20)</td>
</tr>
</tbody>
</table>

Meta-Analysis

<table>
<thead>
<tr>
<th>IV Estimate</th>
<th>Test for overall effect</th>
<th>Heterogeneity [I^2, Qp]</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGES</td>
<td>1.11 (1.05-1.17)</td>
<td>p&lt;0.001 [0%, 0.91]</td>
</tr>
<tr>
<td>ARIC</td>
<td>1.10 (1.05-1.17)</td>
<td>p&lt;0.001 [0%, 0.89]</td>
</tr>
<tr>
<td>FHS</td>
<td>1.09 (1.03-1.15)</td>
<td>p=0.004 [0%, 0.96]</td>
</tr>
<tr>
<td>PREVEND</td>
<td>1.09 (1.03-1.15)</td>
<td>p&lt;0.001 [0%, 0.96]</td>
</tr>
</tbody>
</table>

I^2 reflects heterogeneity between studies with higher values reflecting greater heterogeneity. Qp reflects Cochran’s Q statistic, a test for heterogeneity. AF, atrial fibrillation; BMI, body mass index; HR, hazard ratio; CI, confidence interval; AGES: Age, Gene/Environment Susceptibility—Reykjavik study; ARIC, Atherosclerosis Risk in Communities; FHS, Framingham Heart Study; PREVEND, Prevention of Renal and Vascular End-stage Disease; RS, Rotterdam Study; WGHS, Women’s Genome Health Study. IV, instrumental variable. Model 1: adjustment for age and sex. Model 2: Model 1 + smoking status, alcohol intake. Model 3: Model 2 + potential mediators of BMI-AF association (systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, diabetes, previous coronary heart disease and previous heart failure). Model 4: Model 3 + height.